hypoactive sexual desire disorder (HSDD); sexual interest/arousal disorder
Jump to navigation
Jump to search
Introduction
Low sexual desire in a woman that causes personal distress
Etiology
Epidemiology
- prevalence 12-19%[2]
- increased prevalence in surgically postmenopausal women (26% vs 14%)
History
Complications
- marked personal distress &/or interpersonal difficulty
Management
- couples sex therapy may be beneficial[2]
- treatment of underlying illness
- treatment of depression
- elimination of unnecessary medications
- there is no FDA-approved medication for treatment of HSDD[2]
- transdermal testosterone
- approved in Europe for postmenopausal women who experience HSDD as a result of bilateral oophorectomy[3]
- not recommended in U.S. by Endocrine Society[4]
More general terms
References
- ↑ Leiblum SR et al, Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS) Menopause 2006; 13:46
Kinsberg SA. Prevalence of hypoactive sexual desire disorder in postmenopausal women: Results fromm the WISHeS trial Menopause 2006; 13:10 - ↑ 2.0 2.1 2.2 2.3 Medical Knowledge Self Assessment Program (MKSAP) 16, 17. American College of Physicians, Philadelphia 2012, 2015
- ↑ 3.0 3.1 Nappi RE, Martini E, Terreno E et al Management of hypoactive sexual desire disorder in women: current and emerging therapies. Int J Womens Health. 2010 Aug 9;2:167-75. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21072309
- ↑ 4.0 4.1 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
- ↑ Panay N1, Al-Azzawi F, Bouchard C et al Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010 Apr;13(2):121-31 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20166859